Abstract: The invention relates to a recombinant or synthetic polypeptide characterised in that it includes at least three consecutive repetitions of nonapeptide A N G A G X1 Q X2 X3, in which X1 is selected from D and N, X2 is selected from P and A and X2 is selected from G and A. The inventive polypeptide also preferably includes at least two (2) consecutive repetitions of sequence GDRADGQPA and in an even more preferable embodiment the polypeptide includes an amino-terminal region, a C-terminal region and/or the ptt30 fragment. The invention also relates to malaria vaccines characterised in that they include said peptides.
Abstract: A candidate subunit for a vaccine against malaria caused by P. vivax, known as Pv200L, which is based on N-terminal end portions of the P. vivax MSP-1 protein is disclosed. The subunit is designed for use alone or in formulations, combined with other subunits. The production of recombinant prototypes of the subunit and the design of a production process that can be scaled up for mass production thereof is also disclosed.
Type:
Application
Filed:
November 14, 2006
Publication date:
May 13, 2010
Applicants:
Centro Internacional De Vacunas, Instituto Inmunologia Universidad Del Valle
Inventors:
Augusto Elías Valderama Aguirre, Socrates Herrera Valencia, Myriam Arévalo Ramirez, David Narum